Literature DB >> 12885686

Predictors of warfarin use among Ohio medicaid patients with new-onset nonvalvular atrial fibrillation.

Joseph A Johnston1, Robert J Cluxton, Pamela C Heaton, Jeff J Guo, Charles J Moomaw, Mark H Eckman.   

Abstract

BACKGROUND: Despite demonstrated efficacy in stroke prevention, warfarin is underused in patients with atrial fibrillation (AF). Reasons for warfarin nonuse are unclear.
METHODS: We conducted a retrospective cohort analysis using Ohio Medicaid administrative billing data to ascertain determinants of warfarin use for patients with new-onset nonvalvular AF. The database included data from all institutions, providers, and pharmacies providing services to Ohio Medicaid enrollees. Subjects included all 11699 continuously enrolled fee-for-service recipients of Ohio Medicaid with a new diagnosis of nonvalvular AF between January 1, 1998, and December 31, 2000. We determined incipient warfarin use and presence of risk factors for stroke and hemorrhage by searching claims records for corresponding International Classification of Diseases, Ninth Revision, Clinical Modification codes and National Drug Codes. Univariate and multivariable analyses were performed to examine the association of risk factors with warfarin use.
RESULTS: Only 9.7% of all patients and 11.9% of those without apparent contraindications filled prescriptions for warfarin from 7 days preceding to 30 days after the development of AF. Hypertension and congestive heart failure independently predicted increased warfarin use. Older age (>or=85 years), younger age (<55 years), prior intracranial hemorrhage, prior gastrointestinal hemorrhage, predisposition to falls, alcohol or other drug abuse, renal impairment, and conditions perceived as barriers to compliance predicted decreased warfarin use.
CONCLUSIONS: Few in this cohort of Ohio Medicaid patients with incident AF filled prescriptions for warfarin within 30 days of the diagnosis. Several factors, including alcohol or other drug abuse or dependence, psychiatric disease, homelessness or inadequate housing, and lack of a caregiver, were highly prevalent and seemed to bias against warfarin prescribing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885686     DOI: 10.1001/archinte.163.14.1705

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  16 in total

Review 1.  Balancing ischaemia and bleeding risks with novel oral anticoagulants.

Authors:  Usman Baber; Ioannis Mastoris; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2014-11-04       Impact factor: 32.419

2.  Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation.

Authors:  Colin R Lenihan; Maria E Montez-Rath; Jenny I Shen; John D Scandling; Mintu P Turakhia; Tara I Chang; Wolfgang C Winkelmayer
Journal:  Nephrol Dial Transplant       Date:  2014-10-21       Impact factor: 5.992

3.  Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin.

Authors:  Daniel P Schauer; Charles J Moomaw; Mark Wess; Thomas Webb; Mark H Eckman
Journal:  J Gen Intern Med       Date:  2005-12       Impact factor: 5.128

4.  Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now.

Authors:  Beata V Bajorek; Shu Ren
Journal:  Int J Clin Pharm       Date:  2011-12-17

5.  Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism.

Authors:  Patrick P Kneeland; Margaret C Fang
Journal:  Patient Prefer Adherence       Date:  2010-03-24       Impact factor: 2.711

6.  Falls and Atrial Fibrillation in Elderly Patients.

Authors:  Chen-Ying Hung; Tsu-Juey Wu; Kuo-Yang Wang; Jin-Long Huang; El-Wui Loh; Yi-Ming Chen; Chu-Sheng Lin; Ching-Heng Lin; Der-Yuan Chen; Yih-Jing Tang
Journal:  Acta Cardiol Sin       Date:  2013-09       Impact factor: 2.672

7.  Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation.

Authors:  Mark L Wess; Daniel P Schauer; Joseph A Johnston; Charles J Moomaw; David E Brewer; E Francis Cook; Mark H Eckman
Journal:  J Gen Intern Med       Date:  2008-04       Impact factor: 5.128

8.  Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.

Authors:  Soyon Lee; Rachel Mullin; Jon Blazawski; Craig I Coleman
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

Review 9.  Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis.

Authors:  Victoria L Baczek; Wendy T Chen; Jeffrey Kluger; Craig I Coleman
Journal:  BMC Fam Pract       Date:  2012-02-03       Impact factor: 2.497

10.  The use of warfarin in veterans with atrial fibrillation.

Authors:  Dawn M Bravata; Karen Rosenbeck; Sue Kancir; Lawrence M Brass
Journal:  BMC Cardiovasc Disord       Date:  2004-10-21       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.